These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32867211)

  • 21. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
    Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
    Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer.
    Hua Y; Chen H; Wang L; Wang F; Wang P; Ning Z; Li Y; Liu L; Chen Z; Meng Z
    Cancer Biomark; 2017 Jul; 20(1):95-100. PubMed ID: 28759959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
    Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CEA mRNA identification in peripheral blood is feasible for colorectal, but not for gastric or pancreatic cancer staging.
    Piva MG; Navaglia F; Basso D; Fogar P; Roveroni G; Gallo N; Zambon CF; Pedrazzoli S; Plebani M
    Oncology; 2000 Nov; 59(4):323-8. PubMed ID: 11096345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum CXCL8 and Its Specific Receptor (CXCR2) in Gastric Cancer.
    Pawluczuk E; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Mroczko B
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection.
    Ritchie SA; Akita H; Takemasa I; Eguchi H; Pastural E; Nagano H; Monden M; Doki Y; Mori M; Jin W; Sajobi TT; Jayasinghe D; Chitou B; Yamazaki Y; White T; Goodenowe DB
    BMC Cancer; 2013 Sep; 13():416. PubMed ID: 24024929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients.
    Chen Y; Gao SG; Chen JM; Wang GP; Wang ZF; Zhou B; Jin CH; Yang YT; Feng XS
    Cell Biochem Biophys; 2015 Apr; 71(3):1287-91. PubMed ID: 25486903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of lung cancer based on serum biomarkers by gene expression programming methods.
    Yu Z; Chen XZ; Cui LH; Si HZ; Lu HJ; Liu SH
    Asian Pac J Cancer Prev; 2014; 15(21):9367-73. PubMed ID: 25422226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
    Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
    PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer.
    Knychalski B; Lukieńczuk T
    Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum DJ-1 as a diagnostic marker and prognostic factor for pancreatic cancer.
    He XY; Liu BY; Yao WY; Zhao XJ; Zheng Z; Li JF; Yu BQ; Yuan YZ
    J Dig Dis; 2011 Apr; 12(2):131-7. PubMed ID: 21401899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
    Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
    World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
    Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
    Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CA 242 is a new tumor marker for pancreatic cancer.
    Röthlin MA; Joller H; Largiadèr F
    Cancer; 1993 Feb; 71(3):701-7. PubMed ID: 8431849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
    Haglund C; Lundin J; Kuusela P; Roberts PJ
    Br J Cancer; 1994 Sep; 70(3):487-92. PubMed ID: 8080735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
    Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
    Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study.
    Imaoka H; Mizuno N; Hara K; Hijioka S; Tajika M; Tanaka T; Ishihara M; Hirayama Y; Hieda N; Yoshida T; Okuno N; Shimizu Y; Niwa Y; Yamao K
    Pancreatology; 2016; 16(5):859-64. PubMed ID: 27256641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CXCR2 +1208 CT genotype may predict earlier clinical stage at diagnosis in patients with prostate cancer.
    Franz JM; Portela P; Salim PH; Berger M; Fernando Jobim L; Roesler R; Jobim M; Schwartsmann G
    Cytokine; 2017 Sep; 97():193-200. PubMed ID: 28668699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.